Section 3: Production and Compounding最新文献

{"title":"3PC-018 Time to availability of injectable anticancer drugs for outpatients: reassessment in a French comprehensive cancer centre","authors":"M. Brun, B. Quitte, L. Escalup, A. Hurgon, C. Cros, R. Desmaris, A. Acramel","doi":"10.1136/ejhpharm-2023-eahp.41","DOIUrl":"https://doi.org/10.1136/ejhpharm-2023-eahp.41","url":null,"abstract":"","PeriodicalId":335223,"journal":{"name":"Section 3: Production and Compounding","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131294478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"3PC-016 Does a hospital compressor system continuously deliver medicinal air according to the European Pharmacopoeia?","authors":"E. Gleditsch, R. Nilsen","doi":"10.1136/ejhpharm-2023-eahp.39","DOIUrl":"https://doi.org/10.1136/ejhpharm-2023-eahp.39","url":null,"abstract":"","PeriodicalId":335223,"journal":{"name":"Section 3: Production and Compounding","volume":"103 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124625354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"3PC-001 Prepacked boxes for outpatient parenteral antibiotic therapy (OPAT) – a questionnaire survey on knowledge, opinion and wishes","authors":"T. Truelshøj, C. Olesen, L. Lund Røndbjerg, S. Paarup Kirkeby Herping","doi":"10.1136/ejhpharm-2023-eahp.28","DOIUrl":"https://doi.org/10.1136/ejhpharm-2023-eahp.28","url":null,"abstract":"","PeriodicalId":335223,"journal":{"name":"Section 3: Production and Compounding","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115447964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"3PC-015 In-use stability of Comirnaty and Spikevax clinical solutions: Pfizer-BioNTech and Moderna COVID-19 vaccines: a comparative study from a hospital pharmacy perspective","authors":"J. Hermosilla Fernández, A. Alonso-García, R. Pérez Robles, A. Torrente López, J. Ruiz Travé, N. Navas, J. Cabeza, A. Salmerón García","doi":"10.1136/ejhpharm-2023-eahp.38","DOIUrl":"https://doi.org/10.1136/ejhpharm-2023-eahp.38","url":null,"abstract":"","PeriodicalId":335223,"journal":{"name":"Section 3: Production and Compounding","volume":"87 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127195991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"3PC-028 Formulation of an oral platelet lysate gel to treat chronic graft versus host disease associated oral mucositis: effectiveness in a series of cases","authors":"A. Torrent, T. Lizondo, M. Mestre, M. Lozano, M. López, JR Roma, N. Fernandez, M. Albanell, A. Escolà, D. Soy","doi":"10.1136/ejhpharm-2023-eahp.45","DOIUrl":"https://doi.org/10.1136/ejhpharm-2023-eahp.45","url":null,"abstract":"","PeriodicalId":335223,"journal":{"name":"Section 3: Production and Compounding","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121388809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"3PC-008 Slow anakinra desensitisation protocol design for delayed hypersensibility reaction","authors":"H. Suñer, M. Martín Marqués, O. Esteso Hontoria, C. Badia Santolaria, A. Sanjuán Belda, I. Sacanella Anglès, D. Pascual Carbonell, S. Conde Giner, CJ Cortés Sánchez, A. Garcia Molina, L. Canadell Vilarrasa","doi":"10.1136/ejhpharm-2023-eahp.33","DOIUrl":"https://doi.org/10.1136/ejhpharm-2023-eahp.33","url":null,"abstract":"","PeriodicalId":335223,"journal":{"name":"Section 3: Production and Compounding","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133155735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"3PC-002 HAZARDOUS DRUG AND ANTIBIOTIC RESIDUE SURFACE CONTAMINATION – IS THERE A NEED TO REDUCE EXPOSURE?","authors":"P. Sessink, B. Tans, I. Spriet","doi":"10.1136/ejhpharm-2023-eahp.29","DOIUrl":"https://doi.org/10.1136/ejhpharm-2023-eahp.29","url":null,"abstract":"","PeriodicalId":335223,"journal":{"name":"Section 3: Production and Compounding","volume":"29 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123993362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"3PC-031 A Delphi method to standardise the preparation of autologous serum eye drops?","authors":"L. Champmartin, D. Lannoy, R. Poulenard, P. Agius, O. Márque, E. Bernikier, G. Maillan, PY Robert, J. Jost, V. Ratsimbazafy","doi":"10.1136/ejhpharm-2023-eahp.47","DOIUrl":"https://doi.org/10.1136/ejhpharm-2023-eahp.47","url":null,"abstract":"","PeriodicalId":335223,"journal":{"name":"Section 3: Production and Compounding","volume":"21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122871462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"3PC-014 Metamorphine instead of polysubstance use?","authors":"R. Trittler, A. Abotaleb, C. Böhlke, K. Offner, M. Hug, G. Becker","doi":"10.1136/ejhpharm-2023-eahp.37","DOIUrl":"https://doi.org/10.1136/ejhpharm-2023-eahp.37","url":null,"abstract":"","PeriodicalId":335223,"journal":{"name":"Section 3: Production and Compounding","volume":"30 4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131084551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"3PC-037 Sterility of single use vials when accessed using a closed system transfer device","authors":"JA Schoenenberger Arnaiz, M. Nevot-Blanc, A. Moroba-Estor, M. Gonzalez-Garcia, M. Martínez-Sogués, M. Gilabert-Sotoca","doi":"10.1136/ejhpharm-2020-eahpconf.84","DOIUrl":"https://doi.org/10.1136/ejhpharm-2020-eahpconf.84","url":null,"abstract":"Background and importance It is common practice for compounding facilities in Europe to retain partially used vials of physically stable drugs for future compounding needs; there are discrepancies in accepted beyond use dates (BUD). Canada NAPRA Model Standards specify a BUD of 6 hours based on the risk of microbial contamination for single use vials. Aim and objectives To confirm that using a closed system transfer device (CSTD, ChemoLock), in a class II B2 BSC installed in a class B compliant environment, would prevent microbial contamination of simulated single use vials and maintain their sterility even after repeated access for up to 9 days. Material and methods Under standard compounding procedures, 20 vials of growth media were accessed using ChemoLock vial adaptors. Aliquots (1 mL) were withdrawn and discarded from each vial at 0, 48, 96, 144, 168 and 216 hours. At the end of this 9 day period, samples were incubated in a microbiological laboratory. In order to test for growth of gram positive bacteria, gram negative bacteria, anaerobic microorganisms, yeast and mould, two types of growth media were used: 10 samples with tryptic soy broth (TSB) and 10 samples with fluid thioglycollate medium (FTM). Two temperature ranges (20–25°C and 30–35°C) were used for incubation to ensure optimum growth conditions for different microorganisms. Negative and positive controls for each growth media were also used. Concurrent with testing, each positive control FTM vial was inoculated with one of the following American Type Culture Collection Stock (ATCC) strains: Clostridium sporogenes, Pseudomonas aeruginosa and Staphylococcus aureus, and incubated with the test samples. TSB vials were inoculated with one of the following ATCC stock strains: Bacillus subtilis, Aspergillus brasiliensis and Candida albicans. Results No growth was observed in the negative controls or study samples after 7 days at 20–25°C or after 7 days at 30–35°C. All positive controls showed growth. Conclusion and relevance The study results suggest that single use vial sterility is maintained for up to 9 days when accessed by a ChemoLock CSTD. Prolonged sterility may support BUD extension up 9 days. BUD extension may result in improved medication supply in times of shortage, increased efficiency and could prevent waste of high cost medicines. References and/or acknowledgements ICU Medical has sponsored this study Conflict of interest Corporate sponsored research or other substantive relationships: This research was sponsored by ICU Medical Inc, San Clemente, California, USA","PeriodicalId":335223,"journal":{"name":"Section 3: Production and Compounding","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123760328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}